FDA Investigator Rose Xu
Rose Xu has inspections in 8 countries as of 19 Oct 2023. Rose Xu has collaborated with a combinined 3066 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
16
Last Inspection Date:
19 Oct 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
China,
Austria,
Spain,
United States of America,
Canada,
Brazil,
Portugal,
Germany
Co-Investigator(s):
Adam R Cooke,
Ademola O Daramola,
Alice S Tsao,
Amatul H Marium,
Amy L Singer,
Angela E Glenn,
Anita R Michael,
Ankur C Patel,
Anthony C Warchut,
Arthur T Ogdahl,
Azza Talaat,
Barbara Janine Breithaupt,
Barbara Jwilimczyk Macri,
Barbara M Frazier,
Bill Tacket, Jr,
Carl A Huffman, III,
Carl Lee,
Caroline H Le,
CDR Ileana Barreto Pettit,
CDR Thomas R Berry, PPh,
Charanjeet Jassal,
Cheryl A Clausen,
Christina Capacci Daniel, PhD,
Christopher T Middendorf,
Chryste D Best,
Cynthia Jim, CSO,
Cynthia T Cain,
Darren S Brown,
Daryl A Dewoskin,
Dell S Moller,
Denise M Digiulio,
Djamila Harouaka,
Dongping Dai, PhD,
Douglas G Ng,
Dr. Chunchang Fang,
Dr. Gang Wang, PhD,
Dr. Robert C Horan, MD,
Dr. Sriram Subramaniam, PhD,
Edwin Melendez,
Elizabeth D Gonzales,
Erika V Butler,
Frederick Razzaghi,
Gam S Zamil,
Gamal A Norton,
Gerardo Z Vazquez,
Ginger M Sykes,
Gretchen M Laws,
Gwyn G Dickinson,
Hang N Guo,
Harry J Brewer,
Heika R Tait,
Huiquan Wu,
Inga M Warr,
Iram R Hassan, PhD,
Isabel Y Espinosa,
James A Liubicich,
Jamie L Dion,
Jane L Chang,
Jared P Stevens,
Jawaid Hamid,
Jay T Wong,
Jean A Peeples,
Jennifer L Huntington,
Joanne E King,
Jonathan R Campos,
Jose Acruz Gonzalez,
Jose M Cayuela,
Junho Pak,
Justin A Boyd,
Kara D Dobbin,
Karen G Hirshfield,
Karen L Kosar,
Katherine Szestypalow,
Kathleen D Culver,
Kellia N Hicks,
Kevin D Kallander,
Kimberley A Hoefen,
Lata C Mathew, PhD,
Latorie S Jones,
LCDR Debra Emerson,
LCDR Michael H Tollon,
Libia M Lugo,
Liming Zhang,
Linda F Murphy,
Lindsey M Schwierjohann,
Lisa Sg Shelton,
Mabany Lizardi,
Marcus F Yambot,
Marea K Harmon,
Margaret M Sands,
Mark E Parmon,
Marvin D Jones,
Matthew B Casale,
Matthew R Dionne,
Melissa J Garcia,
Michael E Maselli,
Michael P Sheehan,
Michael R Goga,
Michelle D Haamid,
Michelle Haamid,
Mindy M Chou,
Miral B Patel,
Mizanne E Lewis,
Mra Davism,
Nadeem I Chaudhry,
Nebil A Oumer,
Neil J Bonzagni, PhD MPH,
Nicholas L Paulin,
Nicole E Knowlton,
Patricia D Stahnke,
Patrick C Klotzbuecher,
Paul L Bellamy,
Paul L Figarole, Jr,
Peter E Baker,
Peter S Diak,
Philip F Istafanos, DMV, MS,
Pratik S Upadhyay, DDC,
Qin Xu,
Rachael A Moliver,
Ramesh Sood,
Randy L Clarida,
Renee N Easter,
Robert C Coleman,
Robert C Steyert,
Robert J Ham,
Robert J Martin,
Robert M Barbosa,
Roger F Zabinski,
Ronald T Weber,
Rowena S Nguyen,
Roy C Stephens,
Russell J Glapion,
Saied A Asbagh,
Sandra A Hughes,
Sangeeta M Khurana, PhD,
Santiago Gallardo Johnson,
Satheesh Thomas,
Seneca D Toms,
Simone E Pitts,
Sonya M Edmonds,
Srinivas R Chennamaneni, PhD,
Srira Subramaniam, PhD,
Steven A Gonzales,
Steven C Madzo,
Susan O Oladeji,
Susan P Bruederle,
Susanna E Ford, Analyst,
Tajah L Blackburn,
Tamara L Setzer,
Tamil Arasu, PhD,
Tara K Carmody,
Tara K Normandin,
Theressa B Smith,
Tiki J Dixon,
Timothy T Kapsala,
Tracey L Harris,
Ucheabuchi C Chudi Nwankwor,
Uduak M Inokon,
Unnee Ranjan,
Vincent Thomas,
Vivin George,
Wayne D Mcgrath,
Wendy G Tan, PhD,
Xiomara Copeland,
Ying Zhang,
Yumi J Hiramine,
Yvesna C Blaise,
Zachary A Bogorad,
Zachary L Stamm,
Zakaria I Ganiyu,
Zakaria Wahba,
Zi Qiang Gu
Rose Xu's Documents
Publish Date | Document Type | Title |
---|---|---|
January, 2020 | EIR | Patheon Austria GmbH & CoKG - EIR, 2020-01-31 |
March, 2019 | FDA 483 | Catalent Pharma Solutions, LLC - Form 483, 2019-03-04 |
April, 2016 | FDA 483 | HIKMA FARMACEUTICA (PORTUGAL), S.A - Form 483, 2016-04-12 |
April, 2018 | FDA 483 | Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (FDF Site) - Form 483, 2018-04-03 |
February, 2014 | FDA 483 | TOLMAR INC - Form 483, 2014-02-12 |
May, 2017 | EIR | Bausch & Lomb Incorporated - EIR, 2017-05-26 |
February, 2015 | FDA 483 | CMIC CMO USA CORP - Form 483, 2015-02-13 |
May, 2017 | FDA 483 | Bausch & Lomb Incorporated - Form 483, 2017-05-26 |
February, 2015 | FDA 483 Response | CMIC CMO USA CORP - Form 483R, 2015-03-06 |
January, 2019 | FDA 483 | Amneal Pharmaceuticals of New York, LLC - Form 483, 2019-01-30 |
March, 2019 | EIR | Catalent Pharma Solutions, LLC - EIR, 2019-03-04 |
Experience Redica System's NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more